These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30553825)

  • 1. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
    Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
    Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
    Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
    Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
    Burke NN; Li Y; Deaver DR; Finn DP; Roche M; Eyerman DJ; Sanchez C; Kelly JP
    J Psychopharmacol; 2019 Dec; 33(12):1620-1627. PubMed ID: 31512988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
    Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
    J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
    Falcon E; Maier K; Robinson SA; Hill-Smith TE; Lucki I
    Psychopharmacology (Berl); 2015 Mar; 232(5):907-15. PubMed ID: 25178815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects.
    Zhang H; Torregrossa MM; Jutkiewicz EM; Shi YG; Rice KC; Woods JH; Watson SJ; Ko MC
    Eur J Neurosci; 2006 Feb; 23(4):984-94. PubMed ID: 16519663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant-like effects of buprenorphine in rats are strain dependent.
    Browne CA; van Nest DS; Lucki I
    Behav Brain Res; 2015 Feb; 278():385-92. PubMed ID: 25453747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of opioid modulation in major depressive disorder.
    Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
    Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.
    Almatroudi A; Husbands SM; Bailey CP; Bailey SJ
    J Psychopharmacol; 2015 Jul; 29(7):812-21. PubMed ID: 26045511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
    Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
    Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure to morphine-associated cues increases mu opioid receptor mRNA expression in the nucleus accumbens of Wistar Kyoto rats.
    Dennis TS; Beck KD; Cominski TP; Bobzean SAM; Kuzhikandathil EV; Servatius RJ; Perrotti LI
    Behav Brain Res; 2016 Oct; 313():208-213. PubMed ID: 27421830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
    Robinson SA; Erickson RL; Browne CA; Lucki I
    Behav Brain Res; 2017 Feb; 319():96-103. PubMed ID: 27818236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.
    Carr GV; Bangasser DA; Bethea T; Young M; Valentino RJ; Lucki I
    Neuropsychopharmacology; 2010 Feb; 35(3):752-63. PubMed ID: 19924112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.
    Falcon E; Browne CA; Leon RM; Fleites VC; Sweeney R; Kirby LG; Lucki I
    Neuropsychopharmacology; 2016 Aug; 41(9):2344-51. PubMed ID: 26979295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
    Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
    Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression.
    Browne CA; Smith T; Lucki I
    Eur J Pharmacol; 2020 Apr; 872():172948. PubMed ID: 31991139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.
    Makino M; Kitano Y; Komiyama C; Hirohashi M; Takasuna K
    Br J Pharmacol; 2000 Jul; 130(6):1269-74. PubMed ID: 10903965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
    Beardsley PM; Howard JL; Shelton KL; Carroll FI
    Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.